Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Study reveals dramatic rise in community-acquired MRSA infections
The bacterium Staphyloccus aureus (staph) normally resides on skin and in noses, and typically infects tissues through cuts or rashes. Those infections can remain minor, or lead to
The bacterium Staphyloccus aureus (staph) normally resides on skin and in noses, and typically infects tissues through cuts or rashes. Those infections can remain minor, or lead to
Eligard is a member of a class of drugs known as luteinizing hormone-releasing hormone agonists, also called LHRH agonists. It is used in the treatment of prostate cancer,
This study utilized a clinically relevant model of stroke to validate the NTx-265 dose, timing and regimen anticipated for the proposed phase IIa study. The drugs used, the
The price of the 600mg formulation of Stocrin has been reduced by 20% to $0.76 per day (or $277.40 per patient per year) from $0.95 per day. The
DP-b99 is a unique neuroprotective drug that addresses the array of damaging processes occurring in the brains of stroke patients. After a number of failed trials for neuroprotective
Treatment and follow-up of patients from a phase II clinical study demonstrated that patients in this DR2 and DR4 responder group, who comprise up to 75% of MS
Chronic myocardial ischemia (CMI) is a serious heart condition that involves narrowing of coronary arteries and results in limited blood flow to the heart, affecting hundreds of thousands
The phase II trial will comprise a double blind, placebo-controlled study in 52 patients, with the option to end the trial after treatment of 26 patients if interim
Three phase III clinical studies were conducted in Parkinson’s patients who had developed a shortened response to treatments, called the ‘wearing off phenomenon.’ To assess the drug’s impact,
This study will evaluate the cholesterol-lowering properties of DITPA (3,5-diiodothyropropionic acid), administered in combination with standard statin therapy, in individuals who are unable to achieve targeted cholesterol level